Sen. Richard Blumenthal

This bill extends through October 18, 2021, the order issued by the Centers for Disease Control and Prevention (CDC) titled Temporary Halt in Residential Evictions To Prevent the Further Spread of COVID-19 and published on September 4, 2020. The bill also permits the CDC to further extend the order as it determines necessary.

This resolution expresses the condolences of the Senate regarding the death of the Honorable Mike Enzi, former Senator for Wyoming.

Mapping Housing Discrimination Act This bill provides grants to institutions of higher education to analyze, digitize, and map historic housing discrimination records. The Department of Housing and Urban Development's Office of Policy Development and Research must use data submitted by institutions under the bill to create a publicly available national database of historic housing discrimination records. Historic housing discrimination records are (1) deeds or historic property records that demonstrate housing discrimination, or (2) state or local ordinances that permitted housing discrimination.

Judiciary Accountability Act of 2021 This bill applies certain civil rights and employee protection laws to judicial branch employees. Specifically, the bill applies to judicial branch employees laws that prohibit discrimination based on race, color, religion, sex (including sexual orientation or gender identity), national origin, age, or disability. Further, the bill prohibits retaliation against whistleblowers within the judicial branch. Additionally, the bill establishes (1) the Commission on Judicial Integrity to oversee a program to prevent workplace misconduct; (2) the Office of Judicial Integrity to oversee confidential reporting systems regarding workplace misconduct, training programs on workplace behavior and bystander intervention, and other reporting initiatives regarding employee metrics and demographics; (3) the Special Counsel for Equal Employment Opportunity to investigate alleged workplace misconduct and complaints; and (4) the Office of Employee Advocacy to provide legal assistance, representation, and consultation to judicial employees. Finally, the bill establishes workplace discrimination, harassment, and retaliation as judicial misconduct.

Journalist Protection Act This bill establishes new criminal offenses for intentional acts (or attempts to commit acts) that cause bodily injury to a journalist.

Domestic Workers Bill of Rights Act This bill provides rights and protections for domestic workers (e.g., housekeepers, nannies, caretakers, personal assistants, and chauffeurs), including pay and leave rights, and health and safety protections. Specifically, the bill repeals the exemption of domestic live-in employees from certain minimum wage and maximum hour requirements. Employers must provide written notice of termination and provide at least 30 days of lodging and two weeks of severance pay to terminated live-in employees. Live-in employees also must be provided with reasonable access to telephone and internet service during their employment. The bill requires employers to provide domestic workers with a written agreement covering wages, sick leave, benefits, and other matters. Further, domestic workers may request and be granted changes to work schedules due to personal events. The bill also provides domestic workers with certain privacy rights, extends to domestic workers protections against discrimination in employment, and increases the federal medical assistance percentage (FMAP) for certain Medicaid-funded medical services provided by domestic workers. The Department of Labor must (1) award grants for a domestic worker national hotline for reporting emergencies, training on hazards facing domestic workers, and workforce investment activities for domestic workers; and (2) establish a Domestic Worker Wage and Standards Board to investigate standards in the domestic workers industry. Labor must publish online a document that describes the rights and protections for domestic workers under this bill.

Improving Justice Programs through Science Act of 2021 This bill reestablishes the Science Advisory Board within the Department of Justice (DOJ). Specifically, it provides statutory authority for the board. Previously, the board was created in 2010 by DOJ and terminated in 2018.

Congressional Whistleblower Protection Act of 2021 This bill creates certain administrative and judicial remedies for federal employees whose right to provide information to Congress is interfered with or denied. Under current law, federal employees have the right to petition or furnish information to Congress or to individual Members of Congress, and this right may not be interfered with or denied. The bill explicitly allows employees who are aggrieved by a violation of this right to seek administrative remedies that are currently available to whistleblowers who are fired or experience other forms of retaliation. The bill also establishes a private right of action for aggrieved employees, including the option of a jury trial, if an administrative remedy is not issued within 210 days of a complaint being made. The bill applies to employees and contractors of the executive, legislative, and judicial branches of government, including members of the intelligence community.

Affordable Prescriptions for Patients Act of 2021 This bill prohibits product hopping by drug manufacturers, authorizes the Federal Trade Commission to enforce this prohibition, and imposes limits on patent litigation involving biological products. Generally, product-hopping describes a situation where, when the patents on a reference drug (or biological product) expire, the manufacturer switches to a follow-on product that is covered by a later-expiring patent. Under this bill, a follow-on product is a modified version of the reference drug that shares an indication (what the drug is used for) with the reference drug. The bill presumes product hopping has occurred when a reference drug manufacturer, after receiving notice that the Food and Drug Administration (FDA) has received an application to market a competing generic (or biosimilar) version, takes certain actions such as withdrawing the reference drug from the market and selling a follow-on product. A drug manufacturer may rebut these presumptions by demonstrating that its conduct was not intended to limit competition. The bill also limits in certain instances the number of patents that a reference biological product manufacturer can assert in a patent infringement lawsuit against a company seeking to sell a biosimilar version. Specifically, if the biosimilar manufacturer completes certain actions as part of an abbreviated pathway to get FDA market approval, the bill limits, subject to exceptions and waivers, the number of certain types of patents that the reference product manufacturer may assert, such as patents filed more than four years after the reference product received market approval.

Prescription Pricing for the People Act of 20 21 This bill requires the Federal Trade Commission (FTC) to report about anticompetitive practices and other trends within the pharmaceutical supply chain that may impact the cost of prescription drugs. The FTC also must provide recommendations to increase transparency in the supply chain and prevent anticompetitive practices.